Jae Jun Park
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jae Jun Park has a total of 260 co-authors. Here are the top co-authors by number of shared publications:
- Jae Hee Cheon
Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea
30 shared publications - Tae Il Kim
Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea
30 shared publications - Soo Jung Park
Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea
25 shared publications - Jihye Park
Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea
20 shared publications Jae Myung Cha
Department of Internal Medicine, Kyung Hee University Hospital at Gangdong, Kyung Hee University School of Medicine, Seoul, Republic of Korea
14 shared publications- Hyun Phil Shin
Department of Internal Medicine, Kyung Hee University Hospital at Gangdong, College of Medicine, Kyung Hee University, Seoul 05278, Republic of Korea
11 shared publications
Latest Publications
- Open Access
- 18 November 2026
- Published by AVES YAYINCILIK A.Ş. in Turkish Journal of Gastroenterology
Impact of Infliximab Trough Levels on Clinical Outcomes in Patients with Intestinal Behçet’s Disease
Background/Aims: Few studies have analyzed the association between infliximab trough levels and clinical outcomes in patients with intestinal Behçet disease (BD). The authors investigated the role of infliximab trough levels as an independent predictive factor for clinical outcomes to infliximab in refractory intestinal BD. Materials and Methods: The authors analyzed 46 infliximab trough levels in 33 patients with intestinal BD between November 2019 and October 2025 at Severance Hospital, Seoul, South Korea. Clinical outcomes were compared between the high disease activity (n = 25) and normal or low disease activity (n = 21) groups. Results: In 46 intestinal BD cases with a mean disease duration of 9.8 Å} 8.6 years and a mean infliximab treatment duration of 27.6 months, the infliximab trough level in the high disease activity group was 3.3 μg/mL, whereas it was 7.6 μg/mL in the normal or low disease activity group (P = .039). A mean infliximab level > 7.55 μg/mL (area under the receiver operating characteristic [AUROC]: 0.614, 95% CI: 0.451-0.718, P = .186) was associated with normal or low disease activity, although it did not reach statistical significance. Based on the multivariate logistic regression analysis results, the infliximab trough level was positively associated with normal or low disease activity in intestinal BD (odds ratio [OR]: 1.146, 95% CI: 1.004-1.309, P = .004). C-reactive protein levels (OR: 0.946, 95% CI: 0.904-0.991, P = .019) and the presence of systemic BD manifestations (OR: 0.003, 95% CI: 0.000-0.840, P = .043) were negatively associated with normal or low disease activity. Conclusion: Higher infliximab trough levels were positively associated with normal or low disease activity to infliximab in intestinal BD. Cite this article as: Park J, Mun SY, Park SJ, Park JJ, Kim TI, Cheon JH. Impact of infliximab trough levels on clinical outcomes in patients with intestinal Behçet’s disease. Turk J Gastroenterol. Published online November 18, 2026. doi: 10.5152/tjg.2026.26709.
- 18 November 2026
- Published by AVES YAYINCILIK A.Ş. in Turkish Journal of Gastroenterology
Open AccessImpact of Infliximab Trough Levels on Clinical Outcomes in Patients with Intestinal Behçet’s Disease
Background/Aims: Few studies have analyzed the association between infliximab trough levels and clinical outcomes in patients with intestinal Behçet disease (BD). The authors investigated the role of infliximab trough levels as an independent predictive factor for clinical outcomes to infliximab in refractory intestinal BD. Materials and Methods: The authors analyzed 46 infliximab trough levels in 33 patients with intestinal BD between November 2019 and October 2025 at Severance Hospital, Seoul, South Korea. Clinical outcomes were compared between the high disease activity (n = 25) and normal or low disease activity (n = 21) groups. Results: In 46 intestinal BD cases with a mean disease duration of 9.8 Å} 8.6 years and a mean infliximab treatment duration of 27.6 months, the infliximab trough level in the high disease activity group was 3.3 μg/mL, whereas it was 7.6 μg/mL in the normal or low disease activity group (P = .039). A mean infliximab level > 7.55 μg/mL (area under the receiver operating characteristic [AUROC]: 0.614, 95% CI: 0.451-0.718, P = .186) was associated with normal or low disease activity, although it did not reach statistical significance. Based on the multivariate logistic regression analysis results, the infliximab trough level was positively associated with normal or low disease activity in intestinal BD (odds ratio [OR]: 1.146, 95% CI: 1.004-1.309, P = .004). C-reactive protein levels (OR: 0.946, 95% CI: 0.904-0.991, P = .019) and the presence of systemic BD manifestations (OR: 0.003, 95% CI: 0.000-0.840, P = .043) were negatively associated with normal or low disease activity. Conclusion: Higher infliximab trough levels were positively associated with normal or low disease activity to infliximab in intestinal BD. Cite this article as: Park J, Mun SY, Park SJ, Park JJ, Kim TI, Cheon JH. Impact of infliximab trough levels on clinical outcomes in patients with intestinal Behçet’s disease. Turk J Gastroenterol. Published online November 18, 2026. doi: 10.5152/tjg.2026.26709.
- Open Access
- 31 October 2026
- Published by Korean Association for the Study of Intestinal Diseases in Intestinal Research
- Vol. 24 (4) , 735-743
Clinical usefulness of fecal calprotectin in assessing disease activity and endoscopic remission in intestinal Behçet’s disease
Background/Aims: Intestinal Behçet’s disease (BD) is a manifestation of BD involving the gastrointestinal tract. Although fecal calprotectin (FC) is a useful inflammatory marker, its role in intestinal BD is unclear. Methods: We retrospectively analyzed 78 patients with intestinal BD to evaluate correlations between FC levels and the Disease Activity Index for Intestinal Behçet’s Disease (DAIBD), C-reactive protein (CRP), and erythrocyte sedimentation rate. FC and CRP levels were compared between patients in endoscopic remission and those with active disease. Receiver operating characteristic (ROC) curve analysis was used to evaluate FC’s ability to predict endoscopic activity and ulcer size. Results: FC levels significantly correlated with DAIBD scores (r= 0.253, P= 0.025) and CRP (r= 0.227, P= 0.046). Patients with endoscopically active disease had higher FC (1,124 ± 1,957 μg/g vs. 367 ± 1,208 μg/g; P< 0.001) and CRP levels (16.0 ± 23.7 mg/L vs. 14.4 ± 46.5 mg/L; P= 0.027) than those in remission. Patients with larger ulcers ( ≥ 30 mm) had higher FC levels than those with smaller ulcers (2,212 ± 2,609 μg/g vs. 962 ± 1,822 μg/g; P= 0.034). An FC cutoff level of 176 μg/g discriminated active endoscopic disease (sensitivity 59.3%, specificity 83.3%), with an area under the ROC curve (AUC) of 0.724 (95% confidence interval, 0.605–0.843; P= 0.002), outperforming CRP (AUC, 0.657).Conclusions: FC levels correlated with DAIBD scores and endoscopic inflammation in intestinal BD. FC outperformed CRP in detecting endoscopic activity, supporting its use in disease management.
- 31 October 2026
- Published by Korean Association for the Study of Intestinal Diseases in Intestinal Research
- Vol. 24 (4) , 735-743
Open AccessClinical usefulness of fecal calprotectin in assessing disease activity and endoscopic remission in intestinal Behçet’s disease
Background/Aims: Intestinal Behçet’s disease (BD) is a manifestation of BD involving the gastrointestinal tract. Although fecal calprotectin (FC) is a useful inflammatory marker, its role in intestinal BD is unclear. Methods: We retrospectively analyzed 78 patients with intestinal BD to evaluate correlations between FC levels and the Disease Activity Index for Intestinal Behçet’s Disease (DAIBD), C-reactive protein (CRP), and erythrocyte sedimentation rate. FC and CRP levels were compared between patients in endoscopic remission and those with active disease. Receiver operating characteristic (ROC) curve analysis was used to evaluate FC’s ability to predict endoscopic activity and ulcer size. Results: FC levels significantly correlated with DAIBD scores (r= 0.253, P= 0.025) and CRP (r= 0.227, P= 0.046). Patients with endoscopically active disease had higher FC (1,124 ± 1,957 μg/g vs. 367 ± 1,208 μg/g; P< 0.001) and CRP levels (16.0 ± 23.7 mg/L vs. 14.4 ± 46.5 mg/L; P= 0.027) than those in remission. Patients with larger ulcers ( ≥ 30 mm) had higher FC levels than those with smaller ulcers (2,212 ± 2,609 μg/g vs. 962 ± 1,822 μg/g; P= 0.034). An FC cutoff level of 176 μg/g discriminated active endoscopic disease (sensitivity 59.3%, specificity 83.3%), with an area under the ROC curve (AUC) of 0.724 (95% confidence interval, 0.605–0.843; P= 0.002), outperforming CRP (AUC, 0.657).Conclusions: FC levels correlated with DAIBD scores and endoscopic inflammation in intestinal BD. FC outperformed CRP in detecting endoscopic activity, supporting its use in disease management.
- Open Access
- 10 September 2026
- Published by Korean Association for the Study of Intestinal Diseases in Intestinal Research
Development of liver cirrhosis during azathioprine therapy for inflammatory bowel disease
Development of liver cirrhosis during azathioprine therapy for inflammatory bowel disease
- 10 September 2026
- Published by Korean Association for the Study of Intestinal Diseases in Intestinal Research
Open AccessDevelopment of liver cirrhosis during azathioprine therapy for inflammatory bowel disease
Development of liver cirrhosis during azathioprine therapy for inflammatory bowel disease
- Open Access
- 19 August 2026
- Published by The Editorial Office of Gut and Liver in Gut and Liver
- Vol. 20 (6) , 1017-1025
Clinical Usefulness of Computed Tomography Enterography as a Diagnostic Modality for Isolated Terminal Ileitis
Woojin Ahn, Jung Hyun Ji, Seoyoon Choi, So Jung Han, Jihye Park, Soo Jung Park, Jae Hee Cheon, Tae Il Kim, Jae Jun Park. Gut and Liver -0001;0:. https://doi.org/10.5009/gnl250584
- 19 August 2026
- Published by The Editorial Office of Gut and Liver in Gut and Liver
- Vol. 20 (6) , 1017-1025
Open AccessClinical Usefulness of Computed Tomography Enterography as a Diagnostic Modality for Isolated Terminal Ileitis
Woojin Ahn, Jung Hyun Ji, Seoyoon Choi, So Jung Han, Jihye Park, Soo Jung Park, Jae Hee Cheon, Tae Il Kim, Jae Jun Park. Gut and Liver -0001;0:. https://doi.org/10.5009/gnl250584
- 18 July 2026
- Published by Springer Nature in Digestive Diseases and Sciences
- p. 1-10
Safety and Feasibility of a Patient-Centered Same-Day Polypectomy Referral System: A Single-Center Experience
Background Colon polypectomy is often performed on a separate day following screening colonoscopy, necessitating repeat bowel preparation. Aims We implemented a novel same-day polypectomy referral system to improve patient convenience and evaluated its clinical outcomes and patient satisfaction compared with conventional elective polypectomy. Methods We retrospectively analyzed a prospectively maintained database of patients referred for colon polypectomy at a tertiary center between July and December 2017. Polyp characteristics, bowel preparation quality, procedural outcomes, and complications were compared. Patient satisfaction was assessed using a questionnaire. Results A total of 112 patients were included (same-day polypectomy, n = 57; elective polypectomy, n = 55). The number and location of resected polyps were comparable between groups. Polyps in the same-day group were significantly smaller (6.3 ± 3.2 mm vs. 10.9 ± 8.7 mm, P < 0.001), and bowel preparation quality was lower (mean BBPS 6.8 ± 1.6 vs. 8.4 ± 1.0, P < 0.001). No procedure-related complications occurred in either group. Among respondents, 95% reported satisfaction with the same-day system, most commonly due to avoidance of repeat bowel preparation (71.8%). Conclusion The same-day polypectomy referral pathway appeared feasible in carefully selected patients with non-complex colorectal polyps and was associated with high satisfaction among questionnaire respondents. Lower bowel preparation quality in the same-day group should be considered when interpreting the findings, and the modest sample size precludes definitive conclusions regarding safety.
- 18 July 2026
- Published by Springer Nature in Digestive Diseases and Sciences
- p. 1-10
Safety and Feasibility of a Patient-Centered Same-Day Polypectomy Referral System: A Single-Center Experience
Background Colon polypectomy is often performed on a separate day following screening colonoscopy, necessitating repeat bowel preparation. Aims We implemented a novel same-day polypectomy referral system to improve patient convenience and evaluated its clinical outcomes and patient satisfaction compared with conventional elective polypectomy. Methods We retrospectively analyzed a prospectively maintained database of patients referred for colon polypectomy at a tertiary center between July and December 2017. Polyp characteristics, bowel preparation quality, procedural outcomes, and complications were compared. Patient satisfaction was assessed using a questionnaire. Results A total of 112 patients were included (same-day polypectomy, n = 57; elective polypectomy, n = 55). The number and location of resected polyps were comparable between groups. Polyps in the same-day group were significantly smaller (6.3 ± 3.2 mm vs. 10.9 ± 8.7 mm, P < 0.001), and bowel preparation quality was lower (mean BBPS 6.8 ± 1.6 vs. 8.4 ± 1.0, P < 0.001). No procedure-related complications occurred in either group. Among respondents, 95% reported satisfaction with the same-day system, most commonly due to avoidance of repeat bowel preparation (71.8%). Conclusion The same-day polypectomy referral pathway appeared feasible in carefully selected patients with non-complex colorectal polyps and was associated with high satisfaction among questionnaire respondents. Lower bowel preparation quality in the same-day group should be considered when interpreting the findings, and the modest sample size precludes definitive conclusions regarding safety.
- 1 July 2026
- Published by Korean Association for the Study of Intestinal Diseases in Intestinal Research
Effectiveness of adjunctive use of antibiotics in acute severe ulcerative colitis: a propensity score matching analysis
The exact cause of ulcerative colitis (UC) remains unclear but likely involves an immune response to an unidentified component of gut microbiota. The use of antibiotics in treating acute severe UC (ASUC) remains controversial. This study aimed to assess the benefits of adding antibiotics to corticosteroids for managing ASUC. This retrospective study included patients with ASUC who met the Truelove and Witts diagnostic criteria at admission and received intravenous (IV) corticosteroids, with or without adjunctive antibiotics. Key outcomes included the need for medical and surgical rescue therapy during hospitalization and UC-related re-hospitalization rates at 1 week, 3 months, and 1 year. Propensity score matching (PSM) was employed to minimize selection bias in evaluating the impact of adjunctive antibiotics on clinical outcomes. Of the 386 screened patients, 222 met the inclusion criteria: 75 (33.8%) received IV corticosteroids alone, while 147 (66.2%) received IV corticosteroids combined with antibiotics. After PSM (60 patients per group), the addition of antibiotics showed no significant effect on the need for medical rescue therapy during hospitalization, re-hospitalization, or clinical response based on the partial Mayo score after 1 week of hospitalization (68.3% vs. 60.0%; P= 0.341). Similarly, no significant differences were observed in the need for medical rescue therapy, re-hospitalization, or UC-related surgery rates at 3 months or 1 year (P> 0.05). In patients with ASUC, treatment outcomes did not significantly differ between those receiving IV corticosteroids alone and those receiving a combination of IV corticosteroids and antibiotics, suggesting that adjunctive antibiotic use may offer no added clinical benefits.
- 1 July 2026
- Published by Korean Association for the Study of Intestinal Diseases in Intestinal Research
Effectiveness of adjunctive use of antibiotics in acute severe ulcerative colitis: a propensity score matching analysis
The exact cause of ulcerative colitis (UC) remains unclear but likely involves an immune response to an unidentified component of gut microbiota. The use of antibiotics in treating acute severe UC (ASUC) remains controversial. This study aimed to assess the benefits of adding antibiotics to corticosteroids for managing ASUC. This retrospective study included patients with ASUC who met the Truelove and Witts diagnostic criteria at admission and received intravenous (IV) corticosteroids, with or without adjunctive antibiotics. Key outcomes included the need for medical and surgical rescue therapy during hospitalization and UC-related re-hospitalization rates at 1 week, 3 months, and 1 year. Propensity score matching (PSM) was employed to minimize selection bias in evaluating the impact of adjunctive antibiotics on clinical outcomes. Of the 386 screened patients, 222 met the inclusion criteria: 75 (33.8%) received IV corticosteroids alone, while 147 (66.2%) received IV corticosteroids combined with antibiotics. After PSM (60 patients per group), the addition of antibiotics showed no significant effect on the need for medical rescue therapy during hospitalization, re-hospitalization, or clinical response based on the partial Mayo score after 1 week of hospitalization (68.3% vs. 60.0%; P= 0.341). Similarly, no significant differences were observed in the need for medical rescue therapy, re-hospitalization, or UC-related surgery rates at 3 months or 1 year (P> 0.05). In patients with ASUC, treatment outcomes did not significantly differ between those receiving IV corticosteroids alone and those receiving a combination of IV corticosteroids and antibiotics, suggesting that adjunctive antibiotic use may offer no added clinical benefits.
- Top Cited PapersOpen Access
- 7 March 2026
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 41 (4) , 1223-1231
Clinical Factors Associated With Endoscopic Decompression Failure and Recurrent Sigmoid Volvulus: A Retrospective Cohort Study
Introduction: Although sigmoid volvulus is a potentially life‐threatening condition in elderly patients, its prognostic factors are not well‐known. This study aimed to evaluate clinical outcomes and identify prognostic factors in patients with sigmoid volvulus. Methods: This retrospective cohort study included 96 patients diagnosed with sigmoid volvulus by abdominal CT between January 2005 and January 2023 at two tertiary referral centers. After patients who underwent emergent surgery, refused endoscopic treatment, or experienced spontaneous decompression were excluded, 75 patients were analyzed. Logistic regression identified factors linked to endoscopic decompression failure, while Cox regression analyzed recurrence factors. Results: Among the 75 patients who underwent endoscopic decompression, 60 (80%) showed improvement, whereas 15 (20%) did not. In the logistic regression analysis, younger (≤ 65 years) age (odds ratio [OR], 10.21; 95% confidence interval [CI], 2.21–47.09) and larger (≥ 85 mm) maximum cross‐sectional diameter of distended colon (OR, 5.06; 95% CI, 1.12–22.87) were associated with failure of initial endoscopic treatment. Among the 60 patients who initially improved with endoscopic treatment, cumulative recurrence rates were 30% at 1 year and 36.7% at 3 years. In the Cox regression analysis, a larger (≥ 85 mm) maximum cross‐sectional diameter of distended colon (hazard ratio [HR], 3.27; 95% CI, 1.25–8.59) and a greater (≥ 230 mm) longitudinal axis length of spiraled colon (HR, 5.18; 95% CI, 1.67–16.05) at diagnosis were related to volvulus recurrence. Conclusions: Younger age (≤ 65 years) and severe colonic dilatation (≥ 85 mm) were associated with endoscopic decompression failure, while severe colonic dilatation (≥ 85 mm) and marked longitudinal elongation (≥ 230 mm) were independently related to recurrence. These findings may guide early surgical consultation for high‐risk sigmoid volvulus patients and subsequent resection planning after successful decompression.
- 7 March 2026
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 41 (4) , 1223-1231
Top Cited PapersOpen AccessClinical Factors Associated With Endoscopic Decompression Failure and Recurrent Sigmoid Volvulus: A Retrospective Cohort Study
Introduction: Although sigmoid volvulus is a potentially life‐threatening condition in elderly patients, its prognostic factors are not well‐known. This study aimed to evaluate clinical outcomes and identify prognostic factors in patients with sigmoid volvulus. Methods: This retrospective cohort study included 96 patients diagnosed with sigmoid volvulus by abdominal CT between January 2005 and January 2023 at two tertiary referral centers. After patients who underwent emergent surgery, refused endoscopic treatment, or experienced spontaneous decompression were excluded, 75 patients were analyzed. Logistic regression identified factors linked to endoscopic decompression failure, while Cox regression analyzed recurrence factors. Results: Among the 75 patients who underwent endoscopic decompression, 60 (80%) showed improvement, whereas 15 (20%) did not. In the logistic regression analysis, younger (≤ 65 years) age (odds ratio [OR], 10.21; 95% confidence interval [CI], 2.21–47.09) and larger (≥ 85 mm) maximum cross‐sectional diameter of distended colon (OR, 5.06; 95% CI, 1.12–22.87) were associated with failure of initial endoscopic treatment. Among the 60 patients who initially improved with endoscopic treatment, cumulative recurrence rates were 30% at 1 year and 36.7% at 3 years. In the Cox regression analysis, a larger (≥ 85 mm) maximum cross‐sectional diameter of distended colon (hazard ratio [HR], 3.27; 95% CI, 1.25–8.59) and a greater (≥ 230 mm) longitudinal axis length of spiraled colon (HR, 5.18; 95% CI, 1.67–16.05) at diagnosis were related to volvulus recurrence. Conclusions: Younger age (≤ 65 years) and severe colonic dilatation (≥ 85 mm) were associated with endoscopic decompression failure, while severe colonic dilatation (≥ 85 mm) and marked longitudinal elongation (≥ 230 mm) were independently related to recurrence. These findings may guide early surgical consultation for high‐risk sigmoid volvulus patients and subsequent resection planning after successful decompression.
- Open Access
- 4 February 2026
- Published by Springer Nature in International Journal of Colorectal Disease
- Vol. 41 (1) , 57
Impact of gross tumor morphology on the clinical outcomes of colon cancer: multicenter retrospective cohort study
Purpose: While histopathological features are established prognostic factors in colorectal cancer, the prognostic significance of gross tumor morphology remains unclear. We investigated whether endoscopic gross morphology is associated with clinical outcomes in colon cancer. Methods: We performed a multicenter retrospective analysis of 1,177 patients with colon cancer who underwent curative-intent endoscopic or surgical resection between 2010 and 2019. Tumors were categorized based on endoscopic images as flat/ulceroinfiltrative ( n = 345) or fungating/ulcerofungating ( n = 832). Kaplan–Meier analysis assessed survival outcomes, and Cox proportional hazards models identified independent prognostic factors, adjusting for age, sex, family history, diabetes, CEA, and AJCC 7th edition stage. Results: Patients with flat/ulceroinfiltrative tumors had significantly shorter overall survival (OS, p = 0.001) and disease-free survival (DFS, p = 0.024) than those with fungating/ulcerofungating tumors. In stage II patients, the difference in OS by morphology was more pronounced ( p = 0.004). Multivariate analysis confirmed flat/ulceroinfiltrative morphology as an independent predictor of poor OS (HR 1.61; 95% CI 1.122–2.335; p = 0.010). Other significant predictors included older age (≥ 65 years, HR 1.533; p = 0.021), poor histologic grade (PD vs. WD/MD, HR 5.308; p < 0.001), and advanced stage. Conclusions: Gross endoscopic morphology is an independent prognostic factor in colon cancer. Flat/ulceroinfiltrative tumors are associated with worse outcomes, especially in stage II disease. Gross morphology, readily identifiable at diagnosis, may aid risk stratification and inform decisions regarding adjuvant therapy.
- 4 February 2026
- Published by Springer Nature in International Journal of Colorectal Disease
- Vol. 41 (1) , 57
Open AccessImpact of gross tumor morphology on the clinical outcomes of colon cancer: multicenter retrospective cohort study
Purpose: While histopathological features are established prognostic factors in colorectal cancer, the prognostic significance of gross tumor morphology remains unclear. We investigated whether endoscopic gross morphology is associated with clinical outcomes in colon cancer. Methods: We performed a multicenter retrospective analysis of 1,177 patients with colon cancer who underwent curative-intent endoscopic or surgical resection between 2010 and 2019. Tumors were categorized based on endoscopic images as flat/ulceroinfiltrative ( n = 345) or fungating/ulcerofungating ( n = 832). Kaplan–Meier analysis assessed survival outcomes, and Cox proportional hazards models identified independent prognostic factors, adjusting for age, sex, family history, diabetes, CEA, and AJCC 7th edition stage. Results: Patients with flat/ulceroinfiltrative tumors had significantly shorter overall survival (OS, p = 0.001) and disease-free survival (DFS, p = 0.024) than those with fungating/ulcerofungating tumors. In stage II patients, the difference in OS by morphology was more pronounced ( p = 0.004). Multivariate analysis confirmed flat/ulceroinfiltrative morphology as an independent predictor of poor OS (HR 1.61; 95% CI 1.122–2.335; p = 0.010). Other significant predictors included older age (≥ 65 years, HR 1.533; p = 0.021), poor histologic grade (PD vs. WD/MD, HR 5.308; p < 0.001), and advanced stage. Conclusions: Gross endoscopic morphology is an independent prognostic factor in colon cancer. Flat/ulceroinfiltrative tumors are associated with worse outcomes, especially in stage II disease. Gross morphology, readily identifiable at diagnosis, may aid risk stratification and inform decisions regarding adjuvant therapy.
- Open Access
- 1 January 2026
- Published by XMLink in Yonsei Medical Journal
- Vol. 67 (5) , 400-407
Epidemiological Trends in Inflammatory Bowel Disease in Korea: Age-Related Shifts and Urban-Rural Disparities in a Nationwide Study, 2004–2015
Lee J, et al. Yonsei Med J. 2026 ;67:e20. https://doi.org/10.3349/ymj.2025.0327
- 1 January 2026
- Published by XMLink in Yonsei Medical Journal
- Vol. 67 (5) , 400-407
Open AccessEpidemiological Trends in Inflammatory Bowel Disease in Korea: Age-Related Shifts and Urban-Rural Disparities in a Nationwide Study, 2004–2015
Lee J, et al. Yonsei Med J. 2026 ;67:e20. https://doi.org/10.3349/ymj.2025.0327
- Open Access
- 9 December 2025
- Published by The Editorial Office of Gut and Liver in Gut and Liver
- Vol. 20 (3) , 439-451
Dose-Response Relationship of Niclosamide and Metformin Combination in Apc Min/+ Mice: An Integrated In Vivo and Pharmacokinetic Modeling Study
Joyeon Kang, Dong Keon Kim, Yoojeong Seo, Jongwook Yu, Hyeon Hee Lee, Jihye Park, Jae Jun Park, Jae Hee Cheon, Soo Jung Park, Tae Il Kim. Gut and Liver -0001;0:. https://doi.org/10.5009/gnl250294
- 9 December 2025
- Published by The Editorial Office of Gut and Liver in Gut and Liver
- Vol. 20 (3) , 439-451
Open AccessDose-Response Relationship of Niclosamide and Metformin Combination in Apc Min/+ Mice: An Integrated In Vivo and Pharmacokinetic Modeling Study
Joyeon Kang, Dong Keon Kim, Yoojeong Seo, Jongwook Yu, Hyeon Hee Lee, Jihye Park, Jae Jun Park, Jae Hee Cheon, Soo Jung Park, Tae Il Kim. Gut and Liver -0001;0:. https://doi.org/10.5009/gnl250294